Search Within

Maria C Pietanza

Formats
  1. Meeting Abstract (67)
  2. Journal Article (50)
  3. Book Section (4)
  4. Correspondence (1)
Groups
  1. Department of Medicine (84)
  2. Solid Tumor Oncology Division (81)
  3. Thoracic Oncology (75)
  4. Department of Pathology and Laboratory Medicine (50)
  5. GSK Faculty (48)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (37)

More Groups

People
  1. Mark Kris (50)
  2. Lee Krug (37)
  3. Charles Rudin (33)
  4. William Travis (33)
  5. Gregory Riely (27)
  6. Natasha Rekhtman (24)

More People

Years
  1. 2019 (2)
  2. 2018 (2)
  3. 2017 (8)
  4. 2016 (16)
  5. 2015 (24)
  6. 2014 (15)

More Years

Publications
  1. Journal of Clinical Oncology (29)
  2. Journal of Thoracic Oncology (26)
  3. Modern Pathology (8)
  4. International Journal of Radiation Oncology, Biology, Physics (6)
  5. Laboratory Investigation (6)
  6. Annals of Oncology (4)

More Publications

Publishers
  1. Elsevier Inc. (39)
  2. American Society of Clinical Oncology (29)
  3. Nature Publishing Group (8)
  4. Nature Research (8)
  5. Oxford University Press (6)
  6. American Association for Cancer Research (5)

More Publishers

Results (122)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Metastatic lung carcinoid tumors: Evidence of proliferation rate progression at metastatic sites
    Meeting Abstract

    Desmeules, P.; Sabari, J. K.; Santos-Zabala, M. L.; Litvak, A. M.; Pietanza, M. C.; Poirier, J. T.; Rudin, C. M.; Klimstra, D. S.; Travis, W.; Rekhtman, N.
    Laboratory Investigation (2017)

    Fulltext@MSK | Save
  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: A first-in-human, first-in-class, open-label, phase 1 study
    Journal Article

    Rudin, C. M.; Pietanza, M. C.; Bauer, T. M.; Ready, N.; Morgensztern, D.; Glisson, B. S.; Byers, L. A.; Johnson, M. L.; Burris, H. A. 3rd; Robert, F.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC)
    Meeting Abstract

    Rudin, C. M.; Pietanza, M. C.; Bauer, T. M.; Spigel, D. R.; Ready, N.; Morgensztern, D.; Glisson, B. S.; Byers, L. A.; Johnson, M. L.; Burris, H. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs)
    Meeting Abstract

    Pietanza, M. C.; Krug, L. M.; Waqar, S. N.; Dowlati, A.; Hann, C. L.; Chiappori, A.; Owonikoko, T. K.; Woo, K.; Bensman, Y.; Hurtado, B.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer
    Journal Article

    Reck, M.; Luft, A.; Szczesna, A.; Havel, L.; Kim, S. W.; Akerley, W.; Pietanza, M. C.; Wu, Y. L.; Zielinski, C.; Thomas, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Large cell neuroendocrine carcinoma of the lung: Clinico-pathologic features, treatment, and outcomes
    Journal Article

    Naidoo, J.; Santos-Zabala, M. L.; Iyriboz, T.; Woo, K. M.; Sima, C. S.; Fiore, J. J.; Kris, M. G.; Riely, G. J.; Lito, P.; Iqbal, A.; more...
    Clinical Lung Cancer (2016)

    Fulltext@MSK | Save
  • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial
    Journal Article

    Antonia, S. J.; López-Martin, J. A.; Bendell, J.; Ott, P. A.; Taylor, M.; Eder, J. P.; Jäger, D.; Pietanza, M. C.; Le, D. T.; de Braud, F.; more...
    Lancet Oncology (2016)

    Fulltext@MSK | Save
  • Phase II study of a non-platinum-containing doublet of paclitaxel and pemetrexed with bevacizumab as initial therapy for patients with advanced lung adenocarcinomas
    Journal Article

    Pietanza, M. C.; Hellmann, M. D.; Fiore, J. J.; Smith-Marrone, S.; Basch, E. M.; Schwartz, L. H.; Ginsberg, M. S.; Shouery, M.; Newman, S. K.; Shaw, M.; more...
    Journal of Thoracic Oncology (2016)

    Fulltext@MSK | Save
  • A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer
    Journal Article

    Pietanza, M. C.; Litvak, A. M.; Varghese, A. M.; Krug, L. M.; Fleisher, M.; Teitcher, J. B.; Holodny, A. I.; Sima, C. S.; Woo, K. M.; Ng, K. K.; more...
    Lung Cancer (2016)

    Fulltext@MSK | Save
  • Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets
    Journal Article

    Rekhtman, N.; Pietanza, M. C.; Hellmann, M. D.; Naidoo, J.; Arora, A.; Won, H.; Halpenny, D. F.; Wang, H.; Tian, S. K.; Litvak, A. M.; more...
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save